Safety and Efficacy in Mitral Regurgitation Management with the MitraClip ® G4 System: Insights from a Single-Center Study

• Published in: Journal of cardiovascular development and disease 2024-12, Vol.12 (1), p.4
• Main Authors: Papadopoulos, Georgios E, Ninios, Ilias, Evangelou, Sotirios, Ioannidis, Andreas, Ninios, Vlasis
• Format: Article
• Language: English
• Subjects: Catheters; Chronic obstructive pulmonary disease; Heart attacks; Heart failure; Hemodynamics; Hospitalization; Medical prognosis; MitraClip; mitral regurgitation; Mortality; MR severity; Normal distribution; NYHA class; Pulmonary arteries; QoL; Success; Thoracic surgery; transcatheter edge-to-edge repair
• ISSN: 2308-3425; 2308-3425
• DOI: 10.3390/jcdd12010004

Mitral regurgitation (MR) is a common valvular disorder linked to high morbidity and mortality. For patients unsuitable for surgery, transcatheter mitral edge-to-edge repair (TEER) with the MitraClip G4 system offers an alternative. This study aims to evaluate procedural, echocardiographic, functional, and quality of life (QoL) outcomes in patients who underwent TEER with the MitraClip G4 system, along with possible predictors of New York Heart Association (NYHA) class I at 30 days and at 1 year. Patients with moderate-to-severe (3+) or severe (4+) degenerative MR (DMR) or functional MR (FMR), classified as NYHA class III or IV, and who underwent TEER with the MitraClip G4 system at our center between January 2021 and December 2023 were included. A total of 83 patients [71% FMR, 66% male, median (IQR) age 70 (11) years] underwent TEER, with 100% procedural success. MR ≤ 2+ was achieved in 100% and 98% of patients at 30 days and 1 year, respectively. NYHA class I or II was achieved in 100% and 96.8% of patients at 30 days and 1 year, respectively. The Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved from 51 ± 20 at baseline to 69 ± 15 at 30 days ( < 0.001) and 70.5 ± 15 at 1 year ( < 0.001). Lower baseline N-terminal pro-brain natriuretic peptide (NT-proBNP) predicted achieving NYHA class I at 30 days (HR: 0.63, 95% CI: 0.41-0.95, = 0.030), while lower European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and NT-proBNP predicted it at 1 year [(HR: 0.50, 95% CI: 0.28-0.89, = 0.019), (HR: 0.67, 95% CI: 0.44-0.99, = 0.049), respectively]. The MitraClip G4 system provides significant improvements in MR severity, functional class, and QoL. Lower NT-proBNP and EuroSCORE II were strong predictors of achieving optimal functional status (NYHA class I).